Navigation Links
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
Date:1/9/2009

BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its Phase 1b, 14-day study of hepatitis C virus (HCV) protease inhibitor ITMN-191 (R7227) in combination with Pegasys(R) (interferon alfa-2a) and Copegus(R) (ribavirin) in patients chronically infected with HCV genotype 1. ITMN-191 is being developed in collaboration with Roche.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 80676348. To access the live audio webcast of the conference call, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80676348.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit htpp://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
4. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
10. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
11. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 Global Cervical Dysplasia Market: Scope ... cervical dysplasia market analyzes the current and future ... elaborate executive summary, including a market snapshot that ... The research is a combination of primary ... of our research efforts along with information collected ...
(Date:12/7/2016)... Research and Markets has announced the addition ... Global Forecast to 2021" report to their offering. ... , , The ... growing at a CAGR of 7.3% during the forecast period of 2016 ... cancer and rapidly increasing geriatric population across the globe are the primary ...
(Date:12/7/2016)... Dec. 7, 2016  Palatin Technologies, Inc. ("Palatin") ... on a previously disclosed underwritten public offering of ... acted as sole book-running manager, Roth Capital Partners ... acted as co-manager for the offering. ... in net proceeds, allowing us to continue advancing ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... STAT courier is ... be a convenient service for Texas, they are expanding their presence in Dallas. One ... hiring spree that will bring new jobs to the Dallas and Forth Worth market. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Little Rock, has initiated a ... , According to the National Foundation to End Senior Hunger, Arkansas ranks first ...
(Date:12/8/2016)... ... , ... The Compretta Insurance Agency, a family owned insurance and financial consultation ... County area, is announcing the launch of a charity effort aimed at raising funds ... Pantry has worked for more than 30 years to meet the food needs of ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, ... the most comprehensive mental health systems reform legislation in more than fifty years. ... and the commitment of our elected officials to improving mental health services and ...
(Date:12/7/2016)... ... 07, 2016 , ... OC87 Recovery Diaries (oc87recoverydiaries.com) recounts the ... a unique, personal perspective through animation. , That woman is Sheri Heller, ... her private psychotherapy practice. Sheri’s mother, Pearl, lived with schizophrenia. , By ...
Breaking Medicine News(10 mins):